Adam Bragar News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Fundraising prospects for 2023 across private asset classes haven’t been so grim in a decade.

Allocators need to re-think due diligence in the wake of write-downs in private markets.

Private equity and venture capital assets among the top 200 funds were supersized by returns and deal pace.

The private equity party should run on in 2022, but a handful of factors could have a big impact on how investors commit.

Investors falling head over heels for the pharmaceutical industry Print Bob Jacksha said the New Mexico pension fund already had ‘decent exposure’ to the pharmaceutical industry before the pandemic. The pandemic has heightened investor interest in the pharmaceuticals industry, spurring more capital commitments to specialized private equity and biomedical property funds while managers have gone wild boosting investment in what they view as a growing sector. So far this year, venture capital firms alone have invested $9 billion in 297 biotechnology and pharmaceutical companies worldwide as...